|
|
|
| Testing for BRCA1/2 and ataxiatelangiectasia mutated in men with high prostate indices: An approach to reducing prostate cancer mortality in Asia and Africa |
Jude Ogechukwu Okoye( )
|
| Histopathology Unit, Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, College of Medicine, Nnamdi Azikiwe University, Nnewi Campus, Anambra State, Nigeria |
|
|
|
|
Abstract A recently published review article titled “Current progress and questions in germline genetic of prostate cancer” enumerated some pertinent questions which impact on prostate cancer (PCa) surveillance and management [1]. Literature across the world reveals that the age-standardized incidence rate per 100 000 of PCa is lower in Asia (11.5) and Africa (26.6) when compared with Latin America/Caribbean (56.4), Europe (62.1) and Oceania (79.1); surprisingly the mortality rate per new case is higher in Africa (52.2%) and Asia (39.8%) when compared with Europe (23.9%), Oceania (19.1%), and Latin America/Caribbean (16.8%) [2]. Globally, screening for prostate-specific antigen (PSA) is an approach aimed at identifying PCa at its early stages. However, early identification of individuals at risk of developing aggressive/lethal PCa remains a challenge among clinicians. A follow-up study carried out in the United Kingdom (UK) and Ireland showed that 4.3% and 5.8% of those carrying BRCA1 and BRCA2 mutations developed PCa with a standardized incidence ratio (SIR) of 2.4 and 4.5, respectively [3]. However, the study was not explicit on whether the patients developed lethal or indolent PCa. Another study carried out in the UK revealed that after 3 years of active histological follow-up, 5.2%, 3.4%, 3.0%, and 2.7% of BRCA2 carriers, BRCA1 carriers, BRCA2 non-carriers, and BRCA1 non-carriers developed aggressive PCa, respectively [4]. Nyberg et al. [3] observed that those with a positive family history have SIR of 3.2 and 7.3 for BRCA1 and BRCA2 while those with a negative family history have SIR of 2.3 and 3.9 for BRCA1 and BRCA2, respectively. In the United State (US), a 26 years follow-up exercise revealed that 13.0% of actively monitored men developed PCa, out of which 13.9% developed aggressive PCa [5]. Evidence showed that the frequency of pathogenic mutations was higher in patients with aggressive PCa (6.1%) than in patients with localized PCa (1.4%) [6]. The frequency of BRCA1, BRCA2, and ataxiatelangiectasia mutated (ATM) were higher in aggressive PCa (0.6%, 3.5%, and 1.9%) than in localized PCa (0.4%, 0.8%, and 0.4%, respectively). This suggests that apart from BRCA2 mutation, BRCA1 mutation and ATM play critical roles in the development of aggressive carcinogenesis. However, the extent to which the germline mutations drive carcinogenesis differs with race and across continents. Na et al. [6] showed that carrier rates of pathogenic mutations of BRCA1/2, ATM, and DNA repair genes (DRGs) are higher in Chinese (0.0%/13.6%, 4.6%, and 18.2%) than in Caucasians (0.8%/3.1%, 1.5%, and 5.4%) and African American (0.0%/0.0%, 3.3%, and 3.3%, respectively). Chandrasekar et al. [7] observed that the prevalences of hereditary breast and ovarian cancer (HBOC), hereditary cancer syndrome (HCS), and hereditary prostate cancer (HPC) were higher in African American than in Caucasians while the prevalences of Lynch syndrome (LS) was higher in African American than in Caucasians, with differences of 7.2%, 4.2%, 1.2% and 3.5%, respectively. They observed that the prevalence of HCS, HBOC, and LS connected to family history were higher in African American than in Caucasians with a difference of 12.6%, 15.6%, and 15.6%, respectively. From their study, the prevalences of BRCA1 and BRCA2 were higher in African American (14.3% and 3.6%, respectively) than in Caucasians (5.0% and 3.5%, respectively) while the prevalence of ATM was higher in Caucasians (0.7%) than in African American (0.0%).
|
|
Received: 27 January 2020
Available online: 20 July 2021
|
| About author:: E-mail address: jog.okoye@unizik.edu.ng |
|
|
| [1] |
Isaac WB, Xu J. Current progress and questions in germline genetic of prostate cancer. Asian J Urol 2019; 6:3-9.
|
| [2] |
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality. Eur Urol 2020; 77:38-52.
doi: 10.1016/j.eururo.2019.08.005
|
| [3] |
Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol 2020; 77:24-5.
doi: S0302-2838(19)30675-X
pmid: 31495749
|
| [4] |
Page EC, Bancroft EK, Brook MN, Assei M, Battat MHA, Thomas S, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol 2019; 76:831-42.
doi: 10.1016/j.eururo.2019.08.019
|
| [5] |
Pernar CH, Ebot EM, Petterson A, Graff RE, Giunchi F, Ahearn TU, et al. A prospective study of the association between physical activity and risk of prostate cancer defined by clinical features and TMPRSS:ERG. Eur Urol 2019; 76:33-40.
doi: 10.1016/j.eururo.2018.09.041
|
| [6] |
Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 2017; 71:740-7.
doi: 10.1016/j.eururo.2016.11.033
|
| [7] |
Chandrasekar T, Gross L, Gomella LG, Hegarty SE, Leong JY, Giri VN. Prevalence of suspected hereditary cancer syndromes and germline mutations among a diverse cohort of probands reporting a family history of prostate cancer: toward informing cascade testing for men. Eur Urol Oncol 2020; 3:291-7.
doi: S2588-9311(19)30085-9
pmid: 31278035
|
| [8] |
Buie J, De Riese W, Sharma P. Smaller prostate volume is associated with adverse pathological features and biochemical recurrence after radical prostatectomy. Urol Sci 2019; 30:255-61.
|
| [9] |
Tsang CF, Lai TCT, Lam W, Ho BSH, Ng ATI, Ma WK, et al. Is prostate-specific antigen (PSA) density necessary in selecting prostate cancer patients for active surveillance and what should be the cutoff in the Asian population? Prostate Int 2019; 7:73-7.
doi: 10.1016/j.prnil.2018.03.002
|
| [10] |
Paschalis A, Sheehan B, Riisnaes R, Roddrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol 2019; 76:469-78.
doi: S0302-2838(19)30520-2
pmid: 31345636
|
| No related articles found! |
|
|
|
|
